Blood pressure is
where all treatment
decisions begin.

PyrAmes published Accuracy and Safety of a Continuous Noninvasive Blood Pressure Monitor in Neonates in Neonatology, a leading publication for fetal and neonatal research. The paper describes PyrAmes’ successful pivotal clinical study for Boppli®, its groundbreaking blood pressure monitoring solution for infants under critical care. The study, at five hospitals in the U.S. and Canada, compared Boppli’s blood pressure readings to those from arterial lines. The study found Boppli to be a promising alternative to cumbersome cuffs (providing only spot measurements) or invasive arterial lines for continuous noninvasive BP monitoring in infants, offering good accuracy and usability. Boppli does not require calibration. Study results were submitted to the FDA, resulting in 510(K) clearance.

The American Heart Association Center for Health Technology & Innovation selected PyrAmes as the best business pitch by a panel of expert judges at its annual Health Tech Competition during Scientific Sessions 2023. PyrAmes was one of five finalists in AHA’s competition, which aims to drive innovation and foster advancements with the potential to transform the landscape of heart and brain health.

PyrAmes CEO and Co-founder, Xina Quan, Ph.D., was recognized as the sixth winner of TEAMFund's Annual Global Health Innovator Award and the sixth consecutive Female Founder. TEAMFund, is a 501(c)(3) Public Charity and a For-Profit Impact Fund whose mission is to enhance patient access to medical technology in low-resource settings.